AI GRAND ROUNDS

Authors: GEMINI (RESIDENT), GROK (ATTENDING), KIMI (EXPERT) & ANUPAM SINGH MD (Human in loop)

Department of Medicine, Santosh Medical College.

Click here for App | Agentic Grand Rounds Index

Round 1

User:

Stage 1: History & Presentation (Timestamp: Days Prior to Admission)
A 46-year-old previously healthy female (residing in Ghaziabad, Telemarketing Professional by occupation, is brought to the emergency department via ambulance following a witnessed first-time generalized tonic-clonic seizure with tongue laceration, mouth frothing, and severe respiratory distress requiring emergency endotracheal intubation.
HPI:
- Patient was in her baseline state of health until 2–3 months prior when she developed progressive unintentional weight loss and daily persistent headaches managed with Ibuprofen.
- On the day of admission, family discovered her unresponsive at home experiencing tonic-clonic shaking and urinary incontinence.
- Exam on Arrival: Erythematous, papular raised skin changes directly overlying an old right deltoid tattoo.
- History & Exposures: No prior medical or surgical history. Meds: Ibuprofen 400mg PRN. Lives in Delhi NCR, works from home, has 1 pet dog. Non-smoker, no alcohol or illicit drug use. No family history of autoimmune disease or malignancy.

Resident:

Hello, Chief Resident here.

Key Findings: First-time GTC seizure requiring emergency intubation, 2–3-month history of progressive headache and weight loss, and erythematous papules directly overlying an old tattoo.

Differential Diagnoses:
1. Neurosarcoidosis (50%): The tattoo-associated granulomatous skin reaction combined with subacute CNS symptoms (headaches, seizures) strongly points to systemic sarcoidosis with CNS involvement.
2. CNS Tuberculosis / Tuberculoma (25%): Highly endemic region; subacute weight loss, headache, and new-onset seizure fit central nervous system TB.
3. Neurocysticercosis (15%): A primary cause of adult-onset seizures in India, though less explanatory for the B-symptoms and tattoo reaction.
4. Primary/Metastatic CNS Malignancy (10%): Subacute progressive headache and weight loss culminating in a focal/generalized seizure raise concern for a space-occupying lesion.

Recommended Prioritized Tests:
1. Contrast-Enhanced Brain MRI: To evaluate for leptomeningeal enhancement, parenchymal lesions, or mass effect.
2. Tattoo Lesion Biopsy: For histopathology to identify non-caseating vs. caseating granulomas.
3. High-Resolution Chest CT (HRCT): To assess for hilar lymphadenopathy or pulmonary infiltrates.
4. Lumbar Puncture (CSF Analysis): Cell count, protein, glucose, GeneXpert (TB PCR), fungal stains, cytology, and CSF ACE.
5. Serum ACE and Calcium Levels.

Attending:

Hello Attending Consultant here

Critique: Solid prioritization of endemic CNS infections and sarcoid linkage via tattoo reaction, but overweights neurosarcoidosis without pulmonary data; underemphasizes occult malignancy or autoimmune encephalitis. LP timing post-imaging is correct, yet omit empiric coverage risks in endemic setting. Add EEG and toxicology.

Top 3 DDx:
1. CNS TB (tuberculoma/meningitis)
2. Neurosarcoidosis
3. Metastatic malignancy (occult primary)

Specific points:
1. Secure airway/ventilatory support; load levetiracetam 60 mg/kg.
2. Urgent non-contrast CT head pre-MRI to exclude bleed/mass effect.
3. Empiric anti-TB + steroids if MRI suggestive, pending GeneXpert.
4. Quantiferon-TB, HIV, serum/urine tox screen.
5. Full-skin exam + ophthalmology for uveitis.
6. Tumor markers + CT C/A/P if biopsy non-diagnostic.
7. Hold ACE interpretation—nonspecific; prioritize histology.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Systemic sarcoidosis with neurosarcoidosis — subacute headache/weight loss, first-time seizure, and granulomatous papules erupting within an old tattoo ("tattoo sarcoid") form a coherent multisystem picture.

Top differentials:
1. CNS TB (tuberculoma/TBM): Fits geography, B-symptoms, seizure, and granulomatous skin disease; caseating histology/AFB/GeneXpert would distinguish it. Must be excluded before any steroids.
2. Neurocysticercosis: Commonest adult-onset seizure cause in India, but explains neither weight loss nor tattoo eruption.
3. Occult malignancy (lymphoma/metastasis): Weight loss plus CNS lesion; "great mimicker" of sarcoid — histology must exclude.
4. Autoimmune encephalitis: Less compatible with 2–3-month prodrome.

Key pivot: The tattoo papule — an accessible, low-risk biopsy site that converts an invasive CNS workup into a skin biopsy. Noncaseating granulomas support sarcoid; caseating granulomas redirect to TB. Both prior responses rightly flagged this, but the Resident overweighted sarcoid before excluding TB; the Attending correctly prioritized empiric TB caution.

Next move: Contrast brain MRI first (rule out mass effect), then punch biopsy of the tattoo lesion with AFB stain/GeneXpert, HRCT chest, and CSF analysis. Withhold steroids until TB is excluded.

Teaching pearl: New papules in an old tattoo are a cutaneous sarcoid hallmark — but in TB-endemic regions, sarcoidosis remains a diagnosis of exclusion; biopsy first, steroids later.

Round 2

User:

Stage 2: Physical Examination & Initial Laboratory Evaluation (Timestamp: Admission / Day 1)
Physical Exam: T 37.8°C, HR 104 bpm (tachycardia), BP 173/113 mmHg (hypertensive urgency), RR 22/min (ventilator-dependent). Intubated, sedated. Abdomen: Marked hepatosplenomegaly. Skin: Inflamed, erythematous papular infiltrates across right deltoid tattoo. Neurologic: Intubated, sedated.
Initial Laboratory Panel:
- Metabolic & Electrolyte Panel: Severe Hypercalcemia (Serum Calcium 13.8 mg/dL), Bicarbonate 20 mEq/L (metabolic acidosis), Sodium 134 mEq/L, Potassium 4.1 mEq/L, Serum Creatinine 0.9 mg/dL.
- Endocrine & Vitamin D Workup: Suppressed Serum PTH 6.6 pg/mL (PTH-independent hypercalcemia), Undetectable PTHrP (<0.2 pmol/L), Low 25-Hydroxyvitamin D (14 ng/mL), Markedly Elevated 1,25-Dihydroxyvitamin D (Calcitriol = 447 pg/mL) (confirming extra-renal 1-alpha-hydroxylase production by activated macrophages).
- Hemogram & Hepatic Panel: Hb 11.8 g/dL, Thrombocytopenia (Platelets 125,000/µL) (secondary to splenic sequestration), WBC 8.4 x 10³/µL. Markedly Elevated Alkaline Phosphatase 825 U/L and GGT 482 U/L (cholestatic parenchymal liver disease).
- Infectious & Autoimmune Serology: Quantiferon-TB Gold Indeterminate, AFB sputum/washings negative (3x), HIV 1/2, HBsAg, Anti-HCV, Histoplasma, Coccidioides, Aspergillus, Cryptococcus all negative. c-ANCA, p-ANCA, ANA, SPEP all negative.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Severe PTH-independent hypercalcemia (13.8 mg/dL) secondary to markedly elevated 1,25-dihydroxyvitamin D, marked hepatosplenomegaly, cholestatic liver dysfunction (ALP 825 U/L), tattoo infiltrates, and status-post GTC seizure.

Differential Diagnoses:
1. Disseminated Sarcoidosis (75%): The triad of calcitriol-mediated hypercalcemia (macrophage 1-alpha-hydroxylase), tattoo sarcoidosis, hepatosplenic involvement, and CNS symptoms forms a unified diagnosis.
2. Disseminated Tuberculosis (15%): Can trigger calcitriol-mediated hypercalcemia, B-symptoms, and hepatosplenomegaly in endemic regions, though initial negative AFB and indeterminate Quantiferon lower likelihood.
3. Lymphoma / Lymphoproliferative Malignancy (10%): Calcitriol-mediated hypercalcemia, B-symptoms, and organomegaly can mimic granulomatous disease, though tattoo localization is less typical.

Prioritized Next Steps & Tests:
1. Hypercalcemia & CNS Treatment: Aggressive IV saline hydration, calcitonin, and IV corticosteroids (inhibits 1-alpha-hydroxylase and treats neurosarcoidosis; hold if high clinical suspicion for untreated TB until biopsy).
2. Tattoo Punch Biopsy: Send for histopathology (non-caseating vs. caseating), AFB, and GeneXpert.
3. Contrast Brain MRI: Assess for leptomeningeal enhancement or granulomatous lesions.
4. HRCT Chest: Evaluate for mediastinal

Attending:

Hello Attending Consultant here

Critique: Resident correctly links calcitriol-driven hypercalcemia + tattoo + HSM to sarcoid, but prematurely endorses steroids (risks disseminating occult TB/lymphoma). Indeterminate QFT and endemic setting demand histologic exclusion first. MRI/HRCT sequencing appropriate; omit empiric coverage details and EEG.

Top 3 DDx:
1. Disseminated sarcoidosis (neurosarcoid + hepatic)
2. Disseminated TB (calcitriol hyperCa possible)
3. Lymphoma (occult, macrophage activation)

Specific points:
1. IV NS + calcitonin/bisphosphonate for hyperCa; defer steroids pending biopsy.
2. Urgent tattoo punch bx: H&E, AFB, GeneXpert, culture.
3. Non-contrast CT head → contrast MRI brain (leptomeninges/masses).
4. HRCT chest + contrast CT A/P for nodes/lesions.
5. LP post-imaging: ACE, cytology, TB PCR, flow.
6. Liver US/MRI if ALP persists; avoid blind bx.
7. Repeat QFT + bone marrow if bx nondiagnostic.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Disseminated sarcoidosis with neurosarcoidosis — calcitriol-mediated hypercalcemia (macrophage 1α-hydroxylase), tattoo granulomas, hepatosplenomegaly with cholestatic pattern, and seizure form a coherent multisystem picture.

Top differentials:
1. Disseminated TB: Fits endemic setting, B-symptoms, HSM, and can cause calcitriol hypercalcemia; negative AFB/indeterminate QFT lower but do not exclude. Must be ruled out before steroids.
2. Lymphoma: Calcitriol hypercalcemia, B-symptoms, organomegaly; tattoo localization atypical but histology must exclude.
3. Other granulomatous infections (histoplasmosis, etc.): Serologies negative; less likely.

Key pivot: The calcitriol level of 447 pg/mL — this biochemically confirms extra-renal 1α-hydroxylase activity, narrowing the differential to granulomatous disease or lymphoma and making the tattoo biopsy the decisive, low-risk diagnostic step.

Next move: Punch biopsy of tattoo lesion (H&E, AFB, GeneXpert, culture, flow cytometry) before any steroids. Concurrently: aggressive IV hydration + calcitonin for hypercalcemia, contrast brain MRI, HRCT chest. Steroids only after TB/lymphoma histologically excluded.

Teaching pearl: PTH-independent hypercalcemia with elevated calcitriol is a granulomatous disease signature — but in TB-endemic regions, sarcoidosis remains a diagnosis of exclusion; biopsy first, steroids later.

Round 3

User:

Stage 3: Neuro-Thoracic & Abdominal Imaging (Timestamp: Hospital Days 1-3)
Neuroimaging & Multi-Organ Scanning:
- MRI Brain: T2/FLAIR hyperintensity in bilateral parieto-occipital, right posterior temporal, and right frontal subcortical white matter without restriction or abnormal parenchymal enhancement (PRES vs. neurosarcoid encephalopathy/ictal focus).
- CT Chest: 3.4 x 2.4 cm cavitary lesion in the left upper lobe with an adjacent solid spiculated nodule, multi-station intrathoracic and mediastinal lymphadenopathy, diffuse bilateral airspace disease (acute alveolitis vs. aspiration), and scattered sclerotic bone lesions.
- CT Abdomen/Pelvis: Marked hepatomegaly and moderate-to-severe splenomegaly with micro-nodular parenchymal lesions throughout liver and spleen, ascites, and sclerotic pelvic bone lesions.

Resident:

Hello, Chief Resident here.

Updated Key Findings: MRI demonstrating PRES (secondary to hypertensive/hypercalcemic emergency), LUL cavitary lesion with spiculated nodule, thoracic/abdominal lymphadenopathy, micronodular hepatosplenomegaly, ascites, and sclerotic bone lesions.

Differential Diagnoses:

Attending:

Hello Attending Consultant here

Critique: Incomplete DDx update ignores cavitary LUL + spiculated nodule + sclerotic bones favoring TB/malignancy over pure sarcoid; PRES attribution correct but underplays possible leptomeningeal skip. Defer steroids absolutely; biopsy lung/cavity next, not just tattoo.

Top 3 DDx:
1. Disseminated TB (cavitary + HSM + calcitriol hyperCa)
2. Lymphoma/metastatic solid tumor (spiculated + sclerotic bones)
3. Disseminated sarcoidosis (less likely with cavitation)

Specific points:
1. IR-guided biopsy of LUL cavity/nodule: H&E, AFB, GeneXpert, culture, cytology/flow.
2. Continue IV NS + calcitonin; add zoledronate if Ca refractory; no steroids.
3. Repeat MRI with contrast/MRA to reassess PRES vs granulomatous.
4. Bone scan or PET-CT for sclerotic lesions extent.
5. Ascitic tap: ADA, cytology, TB PCR.
6. Bronchoscopy/BAL if IR delayed.
7. Empiric RIPE only post-biopsy if unstable.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Disseminated tuberculosis — cavitary LUL lesion with spiculated nodule, micronodular hepatosplenic disease, sclerotic bone lesions, calcitriol-mediated hypercalcemia, and seizure (PRES vs. CNS TB) now outweigh sarcoidosis.

Top differentials:
1. Disseminated sarcoidosis: Tattoo granulomas, calcitriol hypercalcemia, HSM fit, but cavitation and sclerotic bones are atypical; remains possible if TB excluded.
2. Lymphoma/metastatic malignancy: Spiculated nodule, sclerotic bones, B-symptoms; calcitriol hypercalcemia possible but less common.
3. Fungal infection (histoplasmosis, etc.): Serologies negative; less likely.

Key pivot: The cavitary LUL lesion with spiculated nodule — this radiographic pattern strongly favors TB or malignancy over sarcoidosis, shifting the diagnostic weight away from the initial sarcoid hypothesis.

Next move: IR-guided biopsy of the LUL cavity/nodule (H&E, AFB, GeneXpert, culture, cytology/flow) before any steroids. Continue hypercalcemia management (IV NS, calcitonin, zoledronate if refractory). Empiric anti-TB therapy only if biopsy confirms or clinical instability demands.

Teaching pearl: Cavitary lung lesions with sclerotic bone metastases in a TB-endemic region should trigger aggressive TB workup — sarcoidosis rarely cavitates, and steroids before TB exclusion can be fatal.

Round 4

User:

Stage 4: Confirmatory Tissue Biopsy & Pathologic Identification (Timestamp: Hospital Days 3-5)
Diagnostic Interventions & Pathology:
- Diagnostic Biopsy: EBUS-TBNA (Endobronchial Ultrasound Transbronchial Needle Aspiration) of mediastinal lymph nodes and skin biopsy of the right deltoid tattoo.
- Histopathology: Demonstration of tightly formed, non-necrotizing Non-Caseating Granulomas composed of epithelioid histiocytes and multinucleated giant cells. GMS (fungal) and Ziehl-Neelsen (AFB) stains completely negative.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Biopsies of the tattoo and mediastinal lymph nodes confirm non-necrotizing non-caseating granulomas. ZN (AFB) and GMS (fungal) stains are negative.

Differential Diagnoses:
1. Disseminated Sarcoidosis (85%): Multi-organ non-caseating granulomas, calcitriol-mediated hypercalcemia, tattoo sarcoid, hepatosplenomegaly, osseous lesions, and hypercalcemia/hypertensive emergency-induced PRES establish this diagnosis.
2. Smear-Negative Disseminated Tuberculosis (10%): Can rarely present with non-caseating granulomas; given the cavitary lesion and endemic setting, final tissue PCR/cultures are needed to fully exclude.
3. Lymphoma with Granulomatous Reaction (5%): Rare secondary tissue reaction masking underlying lymphoproliferative malignancy.

Prioritized Next Steps:
1. Initiate Systemic Corticosteroids: Start IV methylprednisolone immediately to inhibit macrophage 1-alpha-hydroxylase, correct hypercalcemia, and control neurosarcoidosis/systemic inflammation.
2. Tissue GeneXpert / TB PCR & Cultures: Confirm negative mycobacterial/fungal status on tissue aspirates.
3. Taper Acute Hypercalcemia Measures: Transition off calcitonin as corticosteroid effect takes hold.
4. Follow-up Neuroimaging: Repeat brain MRI post-normocalcemia and BP stabilization to confirm resolution of PRES.
5. Ophthalmology Consult: Evaluate for occult ocular involvement.

Attending:

Hello Attending Consultant here

Critique: Resident appropriately upgrades sarcoid probability post non-caseating granulomas, yet prematurely initiates steroids without finalized tissue GeneXpert/cultures—cavitary LUL still mandates TB exclusion to avert dissemination. PRES attribution sound; lymphoma residual risk underweighted.

Top 3 DDx:
1. Disseminated sarcoidosis (tattoo + calcitriol hyperCa + non-caseating)
2. Smear-negative disseminated TB
3. Granulomatous lymphoma reaction

Specific points:
1. Hold steroids pending negative tissue GeneXpert/AFB culture (48-72h).
2. Start IV NS + zoledronate if Ca >12; add steroids only post-TB clear.
3. PET-CT to stage osseous/hepatic burden and guide residual sampling.
4. CSF ACE/cytology if LP feasible post-MRI.
5. Ophthalmology + PFTs for extrapulmonary staging.
6. Serum sIL-2R/ACE as adjunct (nonspecific).
7. Multidisciplinary (pulm/ID/rheum) before immunosuppression.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Disseminated sarcoidosis with neurosarcoidosis — non-caseating granulomas in tattoo and mediastinal nodes, calcitriol-mediated hypercalcemia, hepatosplenomegaly, osseous lesions, and PRES from hypertensive/hypercalcemic crisis form a coherent multisystem picture.

Top differentials:
1. Smear-negative disseminated TB: Cavitary LUL lesion and endemic setting persist; non-caseating granulomas can occur in TB. Tissue GeneXpert/cultures must be negative before steroids.
2. Granulomatous lymphoma reaction: Rare; flow cytometry and cytology on biopsy should exclude.
3. Fungal infection: GMS negative; less likely.

Key pivot: The non-caseating granulomas with negative AFB/GMS stains — this histology strongly supports sarcoidosis, but the cavitary lung lesion demands final TB exclusion via tissue PCR/culture before immunosuppression.

Next move: Await tissue GeneXpert/AFB culture results (48–72h). If negative, initiate IV methylprednisolone for hypercalcemia and neurosarcoidosis. Continue IV NS + zoledronate if calcium remains >12 mg/dL. PET-CT for staging; ophthalmology and PFTs for extrapulmonary assessment.

Teaching pearl: Non-caseating granulomas are not pathognomonic for sarcoidosis — in TB-endemic regions, always confirm negative mycobacterial studies on tissue before committing to steroids, as premature immunosuppression can disseminate occult TB.

Round 5

User:

Stage 5: Final Unifying Diagnosis & Clinical Management (Timestamp: Follow-up & Discharge)
Final Unifying Diagnosis: Severe Multisystem Sarcoidosis (Neurosarcoidosis, Severe Calcitriol-Mediated Hypercalcemia, Cavitary & Alveolar Pulmonary Sarcoidosis, Hepatosplenic Sarcoidosis, Osseous Sarcoidosis, and Cutaneous Tattoo Granulomas).
Treatment Plan:
- Hypercalcemia Emergency Protocol: Aggressive IV Normal Saline hydration, Calcitonin, and immediate high-dose glucocorticoid suppression.
- Immunosuppression: IV Pulse Methylprednisolone 1g daily x 3 days, followed by oral Prednisolone (1 mg/kg/day) with slow taper, combined with targeted Anti-TNF alpha biologic therapy (Infliximab 5 mg/kg) and Mycophenolate Mofetil.
Outcome: Complete normalization of serum calcium (8.8 mg/dL) and calcitriol levels, prompt successful extubation, resolution of encephalopathy/seizures, regression of pulmonary alveolitis, and normalization of cholestatic liver enzymes.

Resident:

Hello, Chief Resident here.

Updated Key Findings: Confirmed severe multisystem sarcoidosis (CNS, cavitary pulmonary, osseous, hepatosplenic, tattoo) presenting with calcitriol-mediated hypercalcemia and PRES. Complete biochemical and neurological recovery achieved following pulse methylprednisolone, infliximab, and mycophenolate mofetil.

Diagnoses:
1. Disseminated Multisystem Sarcoidosis (95%): Confirmed by non-caseating granulomas, calcitriol normalization, and complete clinical response to targeted immunosuppression.
2. Disseminated Tuberculosis (3%): Excluded by negative mycobacterial cultures/PCR and lack of disease progression under potent immunosuppression.
3. Lymphoma / Granulomatous Reaction (2%): Excluded by histology, clinical course, and sustained therapeutic remission.

Management & Next Steps:
1. Maintenance Immunosuppression: Continue slow oral prednisolone taper alongside Infliximab and Mycophenolate Mofetil.
2. Infection Prophylaxis: Initiate Pneumocystis jirovecii pneumonia (PJP) prophylaxis (TMP-SMX) given aggressive multi-agent immunosuppression.
3. Outpatient Surveillance: Perform baseline formal ophthalmologic evaluation, pulmonary function testing, and repeat brain MRI at 3 months.
4. Lab Monitoring: Periodic checks of serum calcium, calcitriol, renal/hepatic panels, and CBC to monitor for drug toxicity and relapse.

Attending:

Hello Attending Consultant here

Critique: Resident correctly affirms sarcoid post-response and negative cultures, but overstates exclusion certainty (cultures need 6-8 wk finalization); infliximab/MMF escalation appropriate for neurosarcoid/refractory hyperCa yet risks infection without documented PJP/VZV prophylaxis timing or baseline IGRA recheck. Outcome validation sound; omit long-term bone-density monitoring.

Top 3 DDx:
1. Multisystem sarcoidosis (confirmed)
2. Smear-negative TB (residual, pending final cultures)
3. Granulomatous lymphoma (excluded by course)

Specific points:
1. Confirm final AFB cultures negative before full steroid taper.
2. Add TMP-SMX PJP + calcium/vit D repletion; DEXA baseline.
3. Serial PFTs, HRCT, MRI brain q3mo; sIL-2R tracking.
4. Ophthalmology q6mo for uveitis/glaucoma.
5. Infliximab levels/antibodies if relapse; hold if infection.
6. Bone scan/PET if osseous symptoms recur.
7. Multidisciplinary sarcoid clinic follow-up.

Expert:

Hello, Expert Clinician here.

Best unifying diagnosis: Severe multisystem sarcoidosis — confirmed by non-caseating granulomas, calcitriol-mediated hypercalcemia, and complete clinical/biochemical response to targeted immunosuppression.

Top differentials:
1. Smear-negative disseminated TB: Residual concern until final AFB cultures (6–8 weeks) are negative; cavitary lesion and endemic setting warrant vigilance.
2. Granulomatous lymphoma reaction: Excluded by histology, clinical course, and sustained remission.
3. Fungal infection: GMS negative; excluded by response.

Key pivot: The complete normalization of calcium and calcitriol with immunosuppression — this biochemical response validates the sarcoidosis diagnosis and confirms the macrophage 1α-hydroxylase mechanism.

Next move: Finalize AFB cultures before full steroid taper. Add TMP-SMX PJP prophylaxis, calcium/vitamin D repletion, and baseline DEXA. Serial monitoring: PFTs, HRCT, brain MRI q3 months, sIL-2R, ophthalmology q6 months. Infliximab levels/antibodies if relapse; hold if infection.

Teaching pearl: Infliximab is the biologic of choice for refractory neurosarcoidosis and calcitriol-mediated hypercalcemia — but always confirm negative mycobacterial cultures before escalating immunosuppression in TB-endemic regions, as premature anti-TNF therapy can disseminate occult TB.

Top 15 Takeaways for Clinicians

  1. Definition of Multisystem Sarcoidosis: Multisystem sarcoidosis is a systemic non-caseating granulomatous disease of unknown etiology characterized by macrophage hyperactivation, CD4+ T-cell alveolitis, and widespread multi-organ infiltration.
  2. Calcitriol-Mediated Hypercalcemia Mechanism: Hypercalcemia in sarcoidosis is PTH-independent and driven by unregulated 1-alpha-hydroxylase expression in activated epithelioid macrophages, converting 25-hydroxyvitamin D into active 1,25-dihydroxyvitamin D (Calcitriol).
  3. Diagnostic Biomarker Signature: Suppressed PTH (<10 pg/mL) combined with markedly elevated serum 1,25-dihydroxyvitamin D (>100–400 pg/mL) is a pathognomonic biochemical signature of granulomatous hypercalcemia.
  4. Tattoo Sarcoidosis Hallmark: Infiltration and papular enlargement within pre-existing tattoo ink sites ("Tattoo Sarcoid") serve as a high-yield, low-risk cutaneous biopsy target to secure non-caseating granulomas.
  5. Neurosarcoidosis Presentation: Neurosarcoidosis occurs in 5–10% of sarcoidosis cases and can present with cranial nerve palsies, aseptic meningitis, seizure activity, or parieto-occipital FLAIR hyperintensities (PRES mimic).
  6. Cavitary & Alveolar Pulmonary Patterns: While bilateral hilar lymphadenopathy and perilymphatic nodules are classic, sarcoidosis can rarely manifest with cavitary lung lesions (Stage III/IV) or diffuse acute alveolitis causing severe hypoxemic respiratory failure.
  7. Hepatosplenic Granulomatous Involvement: Cholestatic liver enzyme elevation (high Alkaline Phosphatase and GGT) with micro-nodular hepatosplenomegaly reflects granulomatous hepatic and splenic infiltration, often causing secondary sequestration thrombocytopenia.
  8. Osseous Sarcoidosis Lesions: Osseous sarcoidosis can present as lytic, cystic, or sclerotic bone lesions across axial and appendicular skeletons, mimicking metastatic bone disease.
  9. Exclusion of Tuberculosis & Endemic Fungi: In TB-endemic regions, tuberculosis must be strictly excluded using tissue GeneXpert/AFB cultures and GMS fungal stains before initiating systemic immunosuppression.
  10. High-Dose Glucocorticoid Induction: Intravenous Methylprednisolone pulse therapy (1g daily x 3 days) rapidly inhibits macrophage 1-alpha-hydroxylase, reversing severe hypercalcemia and controlling acute neurosarcoidosis.
  11. Targeted Anti-TNF Biologic Therapy (Infliximab): Infliximab (5–10 mg/kg), a monoclonal antibody targeting TNF-alpha, is the first-line biologic for refractory neurosarcoidosis and steroid-resistant calcitriol-mediated hypercalcemia.
  12. Second-Line DMARD Options: Mycophenolate Mofetil, Methotrexate, and Azathioprine serve as effective steroid-sparing agents for maintenance therapy in multisystem sarcoidosis.
  13. Pneumocystis Jirovecii (PJP) Prophylaxis: Patients receiving combination therapy with high-dose steroids and anti-TNF biologics require mandatory PJP prophylaxis with Trimethoprim-Sulfamethoxazole (TMP-SMX).
  14. Inaccuracy of Serum ACE Levels: Serum Angiotensin-Converting Enzyme (ACE) levels have low sensitivity and specificity and do not reliably correlate with disease activity or severity.
  15. Multidisciplinary Surveillance Protocol: Comprehensive long-term follow-up requires serial PFTs, HRCT, brain MRI, formal ophthalmologic slit-lamp exams (screening for silent anterior/posterior uveitis), and cardiac MRI.